Entera Bio received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 23, 2023, informing Entera that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. On November 21, 2022, NASDAQ notified the Company that its ordinary shares had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, NASDAQ determined that for the last 14 consecutive business days, from March 3rd through 22nd 2023, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed. Entera is in compliance with all applicable listing standards, and its ordinary shares continues to be listed on The NASDAQ Capital Market.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ENTX:
- Entera Bio Regains Compliance with Nasdaq Listing Requirements
- Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
- Entera Bio announces FDA acceptance of Type D meeting review for EB613 PTH
- Entera Bio to Participate in the SVB Securities Global Biopharma Conference
